Hanmi Pharmaceutical's 3.5 Trillion Won Tech Transfer, Market Impact, and Finding the Next Hanmi Pharmaceutical

However, given the U.S. government's determination to strengthen its artificial intelligence (AI) competitiveness, the long-term direction of data center expansion is unlikely to change.

For Samsung Electronics, in particular, analysis suggests that its current price-to-book ratio (PBR) in the mid-3x range indicates an undervalued state. Based on semiconductor indicators, no objective grounds have been found for the current large-scale selling.

The announcement of economic sanctions against Iran is scheduled for 3 AM tomorrow (Korean time). The recent buying spree by foreign investors in the futures market is noteworthy. The market's anticipation grows for a stock market rebound due to the dissipation of negative news, should the scale of sanctions be smaller than expected. This expectation could positively influence investment sentiment.

The Jackson Hole meeting is scheduled for 11 PM Friday (Korean time). Considering recent solid inflation figures and President-elect Trump's aversion to interest rate hikes, any hawkish remarks from the Federal Reserve (Fed) are likely to remain general. The market is expected to lean towards maintaining the status quo rather than major policy changes.

While there are limits to share acquisition due to the Financial Industry Structure Improvement Act, considering Samsung Electronics' current undervalued stock price and the scheduled large-scale share buyback, a sustained downtrend is not expected. Share buybacks can positively influence stock price defense and appreciation.

Recently, with the rise in lithium carbonate prices and growing expectations for a recovery in the electric vehicle industry, secondary battery related stocks have shown strength. In particular, battery recycling companies like SungEel Hi-Tech and Sebitchem have garnered attention with news of turning profitable. In the LFP (lithium iron phosphate) cathode material sector, LNF was highlighted as a leading company and recommended as a promising stock.

The company has confirmed that the review period is expected to take approximately 30 days. If there are no issues with the review, this upfront payment is expected to be reflected in earnings by the fourth quarter of this year at the latest, which will positively impact Hanmi Pharmaceutical's financial standing.

It is speculated that information may have been unfairly disclosed in advance. This suggests that ordinary investors may be at a disadvantage in terms of access to information.

If Hanmi Pharmaceutical's stock maintains its daily limit up tomorrow, the strength of the bio sector and the KOSDAQ market is expected to continue. However, if the stock opens with a gap up but then retreats, capital inflows may shift back to semiconductor-related stocks such as Samsung Electronics or SK Hynix. This implies that market investment sentiment could transition from the bio sector to other tech stocks.

Such technological differentiation could provide Hanmi Pharmaceutical with a premium and play a crucial role in gaining a competitive edge in the future market. Clinical trials are currently underway, and the market value of the new drug could further increase depending on the results.